Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Science 21 March 2003:
Vol. 299. no. 5614, p. 1845
DOI: 10.1126/science.1078985

Technical Comments

Comment on "The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease"


Osteopontin (OPN), also called early T cell activation gene-1 (Eta-1) or secreted phosphoprotein 1 (Spp1), has important functions in bone metabolism (1, 2) and in inflammation and immunity to infectious diseases (3, 4). Recently, several studies (5-9) have suggested that OPN also plays a crucial role in inflammatory disease models of multiple sclerosis (MS) and rheumatoid arthritis (RA). Chabas et al. (5) first suggested OPN involvement in MS, based on both expression analysis data from MS-affected brains and from studies of mice with the OPN gene deleted; those mice were shown to be partly protected from experimental autoimmune encephalomyelitis (EAE). This was followed up by several papers using other models for RA and MS (8, 9).

The flaw in these data is that they may be explained by linked polymorphic genes, because the mice were not fully backcrossed and typed in these experiments. We have deleted the OPN gene using homologous recombination of strain 129-derived cells, and have subsequently backcrossed it to the C57/BL10 strain with a congenic major histocompatibility complex (MHC) fragment of the q haplotype (B10.Q), which is usually susceptible to EAE, collagen induced arthritis (CIA), and anti-CII antibody transfer induced arthritis (CAIA) (10-12). The gene was shown to be completely inactivated, with no aberrant transcript. The mice were backcrossed for 12 generations to the C57/Black background, and the remaining linked fragment was determined with microsatellite marker [between positions 45 and 64 centiMorgan (cM) on chromosome 5]. In all experiments, both wild-type B10.Q littermates and heterozygous littermates were used as controls.

In contrast to the findings published by Chabas et al. (5) and others, we saw no effect on any inflammatory model tested--EAE, CIA, or CAIA (Table 1). In our EAE experiments we used 25 µg recombinant rat myelin oligodendrocyte glycoprotein (MOG) emulsified in complete Freund's adjuvant (CFA) using a 0-to-8 scoring scale, as described in detail in (10). The mice were followed for 37 days, and 20% of them were in remission at the end of the experiment. A direct comparison with previously published experiments shows that our experimental duration covered the same periods during which the severity differences between the groups were highly significant in the experiments by Chabas et al. [day 35 (5)], as well as in experiments by Jansson et al. [days 14 to 15 (9)]. The wild-type controls in all experiments were of similar severity, but we found no significant difference for our OPN-deleted mice in severity or in remissions at any time point. Possibly, the MOG-induced disease could be different from the MOG peptide-induced disease or proteolipid protein peptide (PLP)-induced disease used in the model of Chabas et al. (5), but that would severely limit the transferability of the data from the Chabas et al. experiments to actual MS. Another possible explanation is that the OPN-deficient mouse used by others still has an aberrant transcript (13), whereas OPN is completely deleted from our model. That difference, however, is unlikely to explain the observed discrepancy. The OPN-/- 129/B6 mice also had a dramatic reduction of acute inflammation induced by monoclonal anti-type II collagen antibodies compared with OPN wt 129/B6 in experiments by Yumoto et al. (8), which used a model very similar to the arthritis induced in our mice (12). This is important, because this model is an acute inflammation but is not dependent on T or B cells.

Table 1. Severity, incidence, and onset in CIA, EAE, and CAIA. wt, wild-type.


Model Genotype Mean maximum score (±SD) Incidence, % (numbers) Mean onset day (± SD)

CIA wt/wt 20.8 (±7.2) 54.5 (6/10) 44.5 (±6.2)
opn-/wt 23.7 (±5.8) 50.0 (3/6) 47.3 (±9.3)
opn-/opn- 23.8 (±2.9) 50.0 (4/8) 41.3 (±6.8)
EAE opn-/wt 6.1 (±0.2) 91.7 (11/12) 13.2 (±0.9)
opn-/opn- 6.3 (±0.2) 100 (10/10) 12.8 (±0.6)
CAIA opn-/wt 3 (±0) 25 (1/4) 3 (±0)
opn-/opn- 7 (±1.1) 36 (3/10) 7.33 (±1.2)

It is more likely that the observations of Chabas et al. (5) and others (6-9) resulted from one or several polymorphic genes derived from strain 129 and linked to the OPN locus. In these experiments--in which mixed or incompletely backcrossed 129/B6 mice containing homozygous OPN or homozygous "wild type" were used--a large and unidentified fragment on chromosome 5, derived from 129 and containing a deleted OPN gene, was compared with a corresponding fragment from B6. Thus, any polymorphic genes in this fragment, which contained thousands of genes, could be of importance. Indeed, several quantitative trait loci (QTLs) have been observed on chromosome 5 in linkage studies of Lyme arthritis (14) and EAE (15). In addition, a gene within an earlier-defined QTL in a homologous region in rats has recently been cloned that dramatically affects the severity of arthritis and EAE (16). This region has also long been known to control traits like resistance to Rickettsia infection, and the polymorphism of the associated haplotype has been found to vary extensively among strains (17). Thus, this region--as is probable with most parts of the genome--contains many polymorphic genes that can potentially have an important influence on inflammatory diseases. A list of some closely linked polymorphic genes that potentially could influence an inflammatory response is provided in Table 2.

Table 2. Genes closely linked to OPN (Spp1) that have potential inflammatory functions and their position along chromosome 5 (in cM).


Symbol Name Position Function Reference 

Cxcl1 Chemokine (C-X-C) ligand 1  51 Chemoattractant, APC activation (18, 19)
Cxcl2 Chemokine (C-X-C) ligand 2  51 Chemoattractant, neutrophil Ca2+ release/activation (20, 21)
Cxcl15 Chemokine (C-X-C) ligand 15  51.5 Chemoattractant, hematopoiesis    (22)
Cxcl5 Chemokine (C-X-C) ligand 5  53 Chemoattractant, neutrophil Ca2+ release/activation (21, 23)
Cxcl9 Chemokine (C-X-C) ligand 9  53 Chemoattractant, anti-angiogenesis (24, 25)
Cxcl10 Chemokine (C-X-C) ligand 10  53 Chemoattractant, anti-angiogenesis (24, 26)
Bmp3 Bone morphogenic protein 3  55 Bone metabolism, TGF beta signalling (27, 28)
Fgf5 Fibroblast growth factor 5  55 Fibroblast proliferation, brain development (29, 30)
Sparcl1 SPARC-like 1  55 B cell development (31, 32)
*Spp1 Secreted phosphoprotein 1 (OPN) 56
Tsz1 Thymus size 1  56 Thymus size (polymorphic between C56/BL6 and C56/BL10)    (33)
Selpl Platelet selectin ligand 64 Leucocyte tethering/rolling (34, 35)
Lnk Linker of T cell pathways 65 Cytokine signaling and hematopoietic homeostasis (36, 37)
Nos1 Nitric oxide synthase 1, neuronal 65 Inflammation, asthma (38, 39)

There are several difficulties in using knockout mice in providing conclusive evidence for genes in disease traits, like the role of OPN in inflammatory diseases. A common pitfall is when wild-type mice and not littermates are used as controls: In that situation, any gene in the genome that differs between the embryonic stem (ES) cell and the backcrossed parental cell may play a role. Preferably, heterozygous littermates should be included, because dominant genes in the linked fragment will be neutralized. However, a recessive effect closely linked to the gene of interest is almost impossible to exclude if the knockout is created with ES cells of a different genotype than in the mouse used later in the study. In addition, a parental strain 129 control is not proper as a control for many different reasons. The origins of 129 strains vary and are most likely different from those of the abnormal strain that grows from a somatically mutated ES cell line that has been adapted for growth in a laboratory. Furthermore, it is well known that isolated congenic fragments will control traits different from their role in the parentals because of interactions with the rest of the genome, as well as through splitting of selected gene pairs in the borders of the congenic fragments. Therefore, it is of general and crucial importance to identify the naturally selected polymorphisms controlling the diseases or traits of interest.

We emphasize that we do not question an important and potential role of OPN in various biological contexts (1, 2). The role for OPN in inflammatory disease is still an open issue. The lack of effect in the OPN-deleted mouse is most likely explained by the influence of other genes that may replace the role of OPN. Identifying the OPN-linked polymorphic genes that exert a strong influence on arthritis and encephalomyelitis therefore represents a challenging and important task.

Thomas Blom
Department of Medical
Inflammation Research
Lund University
Sölvegatan 19
Lund 22184, Sweden
Ahnders Franzén
Dick Heinegård
Department of Connective Tissue Biology
Lund University
Rikard Holmdahl
Department of Medical
Inflammation Research
Lund University

REFERENCES

1. F. P. Reinholt, K. Hultenby, A. Oldberg, D. Heinegard, Proc. Natl. Acad. Sci. U.S.A. 87, 4473 (1990) [Abstract/Free Full Text].
2. D. T. Denhardt and M. Noda, J. Cell. Biochem. Suppl. 31, 92 (1998) .
3. S. Ashkar, et al., Science 287, 860 (2000) [Abstract/Free Full Text].
4. A. W. O'Regan, et al., Am. J. Respir. Crit. Care. Med. 164, 2243 (2001) [Abstract/Free Full Text].
5. D. Chabas, et al., Science 294, 1731 (2001) [Abstract/Free Full Text].
6. M. Sakata, et al., J. Rheumatol. 28, 1492 (2001) [Abstract/Free Full Text].
7. S. Ohshima, et al., Arthritis Rheum. 46, 1094 (2002) [CrossRef] [Web of Science] [Medline].
8. K. Yumoto, et al., Proc. Natl. Acad. Sci. U.S.A. 99, 4556 (2002) [Abstract/Free Full Text].
9. M. Jansson, V. Panoutsakopoulou, J. Baker, L. Klein, H. Cantor, J. Immunol. 168, 2096 (2002) [Abstract/Free Full Text].
10. K. B. Abdul-Majid, et al., J. Neuroimmunol. 111, 23 (2000) [CrossRef] [Web of Science] [Medline].
11. K. Gustafsson, M. Karlsson, L. Andersson, R. Holmdahl, Eur. J. Immunol. 20, 2127 (1990) [Web of Science] [Medline].
12. A. C. Johansson, A. S. Hansson, K. S. Nandakumar, J. Backlund, R. Holmdahl, J. Immunol. 167, 3505 (2001) [Abstract/Free Full Text].
13. S. R. Rittling, et al., J. Bone Miner. Res. 13, 1101 (1998) [CrossRef] [Web of Science] [Medline].
14. M. R. Potter, et al., Infect. Immun. 70, 1372 (2002) [Abstract/Free Full Text].
15. J. Karlsson, et al., J. Immunol. 170, 1019 (2003) [Abstract/Free Full Text].
16. P. Olofsson, et al., Nature Genet. 33, 25 (2003) [CrossRef] [Web of Science] [Medline].
17. T. R. Jerrells and J. V. Osterman, Infect. Immun. 31, 1014 (1981) [Abstract/Free Full Text].
18. B. H. Cochran, A. C. Reffel, C. D. Stiles, Cell 33, 939 (1983) [CrossRef] [Web of Science] [Medline].
19. A. R. Glabinski, V. K. Tuohy, R. M. Ransohoff, Neuroimmunomodulation 5, 166 (1998) [CrossRef] [Web of Science] [Medline].
20. P. Tekamp-Olson, et al., J. Exp. Med. 172, 911 (1990) [Abstract/Free Full Text].
21. A. Wuyts, et al., J. Immunol. 157, 1736 (1996) [Abstract].
22. D. L. Rossi, et al., J. Immunol. 162, 5490 (1999) [Abstract/Free Full Text].
23. J. B. Smith and H. R. Herschman, J. Biol. Chem. 270, 16756 (1995) [Abstract/Free Full Text].
24. M. R. Horton, et al., J. Biol. Chem. 273, 35088 (1998) [Abstract/Free Full Text].
25. J. M. Farber, Proc. Natl. Acad. Sci. U.S.A. 87, 5238 (1990) [Abstract/Free Full Text].
26. C. S. Tannenbaum, T. J. Koerner, M. M. Jansen, T. A. Hamilton, J. Immunol. 140, 3640 (1988) [Abstract].
27. M. E. Dickinson et al., Genomics 6, 505 (Mar 1990).
28. C. Faucheux, F. Ulysse, R. Bareille, A. H. Reddi, J. Amedee, Biochem. Biophys. Res. Commun. 241, 787 (1997) [CrossRef] [Web of Science] [Medline].
29. M. M. Dickie, Mouse Newslett. 29, 39 (1963) .
30. K. Ozawa, T. Uruno, K. Miyakawa, M. Seo, T. Imamura, Brain Res. Mol. Brain Res. 41, 279 (1996) [Medline].
31. K. Oritani and P. W. Kincade, J. Cell Biol. 134, 771 (1996) [Abstract/Free Full Text].
32. K. Oritani, et al., Blood 90, 3404 (1997) [Abstract/Free Full Text].
33. L. Peleg and M. N. Nesbitt, J. Hered. 75, 126 (1984) [Abstract/Free Full Text].
34. L. Xia, et al., J. Clin. Invest. 109, 939 (2002) [CrossRef] [Web of Science] [Medline].
35. J. Yang, J. Galipeau, C. A. Kozak, B. C. Furie, B. Furie, Blood 87, 4176 (1996) [Abstract/Free Full Text].
36. L. Velazquez, et al., J. Exp. Med. 195, 1599 (2002) [Abstract/Free Full Text].
37. S. Takaki, et al., J. Biol. Chem. 272, 14562 (1997) [Abstract/Free Full Text].
38. C. R. Lyons, G. J. Orloff, J. M. Cunningham, J. Biol. Chem. 267, 6370 (1992) [Abstract/Free Full Text].
39. G. T. De Sanctis, et al., J. Exp. Med. 189, 1621 (1999) [Abstract/Free Full Text].
30 September 2002; accepted 31 December 2002
10.1126/science.1078985
Include this information when citing this paper.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
T-bet-dependent expression of osteopontin contributes to T cell polarization.
M. L. Shinohara, M. Jansson, E. S. Hwang, M. B. F. Werneck, L. H. Glimcher, and H. Cantor (2005)
PNAS 102, 17101-17106
   Abstract »    Full Text »    PDF »
Enhanced autoimmunity, arthritis, and encephalomyelitis in mice with a reduced oxidative burst due to a mutation in the Ncf1 gene.
M. Hultqvist, P. Olofsson, J. Holmberg, B. T. Backstrom, J. Tordsson, and R. Holmdahl (2004)
PNAS 101, 12646-12651
   Abstract »    Full Text »    PDF »
Immune Therapy for Autoimmune Diseases.
L. Steinman (2004)
Science 305, 212-216
   Abstract »    Full Text »    PDF »
Osteopontin: Roles in Implantation and Placentation.
G. A. Johnson, R. C. Burghardt, F. W. Bazer, and T. E. Spencer (2003)
Biol Reprod 69, 1458-1471
   Abstract »    Full Text »    PDF »



To Advertise     Find Products

ADVERTISEMENT

Featured Jobs

Science. ISSN 0036-8075 (print), 1095-9203 (online)